Pharming Group N.V.

Stage 4 · Declining · week 22

As of Oct 22, 2026, Pharming Group is in Stage 4, the downtrend phase, now in week 22 (since May 21, 2026). It closed at $10.67, 49.6% below its 52-week high and below its 200-day average, which is falling.

$10.67

+10.57% today

$755M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PHAR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 30w

S2 41w

S4 22w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 4w → S2 5w → S3 4w → S4 7w → S1 3w → S2 6w → S3 1w → S4 30w → S1 13w → S2 8w → S3 9w → S2 41w → S3 12w → S4 22w current

Total tracked: 166 weeks across 14 stage runs.

PHAR among Biotechnology250th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…250	PHARPharming Group N.V.	Stage 4 · wk 22	39	−0.9%

vs 52W High

-49.6%

$9.11 lo$21.18 hi

49.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 22

1w13w26w

Week 22, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-23.6%

200 DMA: $13.97 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.91x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-0.9%

-15.4%

-35.9%

YTD

-37.7%

-21.4%

Scan Membership

Breakout Watch

Latest: 2025-05-19

8 appearances in last 60 days. First seen: 2022-08-25.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 22 · Vol 0.91x

2026-10-21S4

Wk 22 · Vol 0.42x

2026-10-20S4

Wk 21 · Vol 0.24x

2026-10-19S4

Wk 21 · Vol 0.51x

2026-10-16S4

Wk 21 · Vol 0.34x

2026-10-15S4

Wk 21 · Vol 0.28x

2026-10-14S4

Wk 21 · Vol 0.15x

2026-10-13S4

Wk 20 · Vol 1.10x

2026-10-12S4

Wk 20 · Vol 0.28x

2026-10-09S4

Wk 20 · Vol 0.12x

2026-10-08S4

Wk 20 · Vol 0.18x

2026-10-07S4

Wk 20 · Vol 0.14x

Moving averages & range

50 DMA

$10.71

200 DMA

$13.97

52W High

$21.18

52W Low

$9.11

5D Low

$9.11

Resistance levels (recent highs)

20d High

$10.67

60d High

$12.35

120d High

$16.40

250d High

$21.18

Next resistance

+15.7%

to 60d High

P/E (TTM)

82.1

Forward 27.7

Earnings Growth (YoY)

-62.9%

Revenue -3.2%

ROE

+3.6%

Profit margin +2.5%

Dividend Yield

0.00%

P/B 2.8

Pharming Group: quick answers

What stage is Pharming Group in?

As of Oct 22, 2026, Pharming Group (PHAR) is in Stage 4, the downtrend phase. It entered Stage 4 on May 21, 2026 and is in week 22. What the four stages mean

Is Pharming Group in an uptrend?

No. Pharming Group is in a Stage 4 downtrend. It trades 23.6% below its 200-day average, which is falling.

How far is Pharming Group from its 52-week high?

Pharming Group closed at $10.67 on Oct 22, 2026, 49.6% below its 52-week high of $21.18. Its 52-week low is $9.11.

How has Pharming Group performed over the past year?

As of Oct 22, 2026, Pharming Group is down 21.4% over the past year and down 37.7% so far in 2026.

Which sector and industry is Pharming Group in?

Pharming Group is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.